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Introduction: Cutaneous T cell lymphoma (CTCL) encompasses a heterogeneous group of 
neoplasms of skin-homing T cells, which includes mycosis fungoides, the most common form, 
and Sézary syndrome, the leukemia equivalent of mycosis fungoides. Histone deacetylase 
inhibitors are currently under investigation for their therapeutic value in a variety of conditions. 
Through multiple mechanisms, they induce apoptosis or inhibition of tumor cell growth. Some 
studies have also shown histone deacetylase inhibitors to have synergistic activity with existing 
therapeutic agents in selected conditions. Romidepsin is a histone deacetylase inhibitor with 
a promising efficacy and safety profile that may represent a valuable treatment alternative for 
patients with treatment-resistant mycosis fungoides and Sézary syndrome.
Aims: To review emerging evidence regarding the use of romidepsin in the management of 
treatment-resistant CTCL.
Evidence review: There is evidence that romidepsin can induce significant and durable 
responses in patients with refractory CTCL. In two independent Phase II trials including a total 
of 167 patients with CTCL, there was an overall response rate of 34% with a partial response of 
28% and complete response rate of 6%. The most frequent toxicities reported from the Phase II 
trials were nausea, vomiting, fatigue, anorexia, and dysgeusia.
Clinical potential: Romidepsin may be an effective therapeutic option for patients with CTCL 
who have had treatment failure with multiple standard treatment modalities.
Keywords: cutaneous T cell lymphoma, mycosis fungoides, Sézary syndrome, romidepsin, 
histone deacetylase inhibitor, treatment
Core evidence clinical impact summary for romidepsin in CTCL
Outcome measure Evidence Implications
Disease-oriented evidence
Response rate Substantial Patients with refractory CTCL have 
partial and complete response to drug.
improvement in quality of life Moderate Patients had a meaningful reduction in 
pruritus.
Patient-oriented evidence
Safety and tolerability Moderate Grade 3 and 4 toxicities were observed 
but infrequently led to dose limitations. 
Economic evidence
Health care resource utilization Limited Direct cost of the drug at the approved 
dosing level is currently higher than 
other novel agents used in CTCL.
Cost-effectiveness No evidenceCore Evidence 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2
Poligone et al
Background
Cutaneous T-cell lymphoma (CTCL) encompasses a heterog-
enous group of neoplasms of skin-homing T cells. CTCLs 
represent approximately 75% of all primary cutaneous 
lymphomas, and half of these are the most common type, 
mycosis fungoides.1 There are 2000 to 3000 new cases of 
CTCL diagnosed per year.2 Sézary syndrome, the leukemic 
equivalent of mycosis fungoides, is defined as having the 
triad of erythroderma, generalized lymphadenopathy, and 
the presence of neoplastic T cells in the skin, lymph nodes, 
and peripheral blood. Sézary syndrome is rare, comprising 
less than 5% of all CTCLs. In general, therapies for mycosis 
fungoides are most effective at controlling early-stage and 
previously untreated disease, whereas later-stage disease, 
such as erythrodermic CTCL, and previously treated disease 
tend to be more resistant. The novel therapeutic option of 
histone deactylase inhibitors is being advanced in the hope of 
decreasing the morbidity and mortality of this disease. This 
review seeks to examine the basic science behind histone 
deacetylase inhibitors and the clinical trials investigating the 
use of one such histone deacetylase inhibitor, romidepsin, in 
patients with CTCL.
Methods
We reviewed the literature by using the PubMed database. 
We used the search terms “depsipeptide” and “lymphoma”. 
The search produced 80 articles. Of these, two were reviews 
of CTCL therapy, nine were on the subject of histone 
deacetylase inhibitors, and 10 were specifically concerning 
romidepsin use in CTCL.
Cutaneous T cell lymphoma
CTCL is a broad term encompassing a group of cutaneous 
lymphomas in which T cells are the cell of origin causing 
disease. Within this type of cutaneous lymphoma, mycosis 
fungoides represents the majority of cases, whereas Sézary 
syndrome is very rare.
The incidence of mycosis fungoides is 0.41/100,000 
per year.2 This rate is increasing. Although it does affect 
all races, in the US it occurs relatively more often in black 
people and in males. It is typically seen in older adults, with 
a median age of 55–60 years at diagnosis.3 The disease is 
typically a chronic, slowly progressive disease that evolves 
through a patch stage (consisting of flat, scaly red-brown, 
hyperpigmented, or hypopigmented patches) and a plaque 
stage (in which the patches become infiltrated), and may 
eventually progress to the tumor stage (in which nodules 
appear), although the disease can have any of these lesions, 
as well as erythroderma, at presentation. The initial skin 
lesions tend to involve areas of skin not exposed to the sun, 
classically the buttocks and covered sites of the trunk and 
limbs.
In general, mycosis fungoides affects an older popula-
tion and has a long evolution. Many patients do not progress 
beyond the patch/plaque stage. Independent markers of a 
poor prognosis include age of onset .60 years, cutaneous 
and lymph node stage of disease, elevated serum lactate 
dehydrogenase, folliculotropic disease, and thickness of the 
infiltrate in plaque-stage mycosis fungoides.4 Once tumors 
develop or lymph node involvement occurs, the prognosis 
becomes guarded and mycosis fungoides can be fatal.
Sézary syndrome accounts for less than 5% of all CTCL 
and occurs only in adults. It is defined as having the triad of 
erythroderma, generalized lymphadenopathy, and neoplastic 
T cells (Sézary cells) in the skin, lymph nodes, and peripheral 
blood. Criteria for the diagnosis have evolved over time, and 
currently include having a T cell clone in the peripheral blood 
and an absolute Sézary cell count of at least 1000 cells/µL or 
a CD4:CD8 ratio .10.5 The erythroderma may be associated 
with marked exfoliation, edema, and lichenification. It can be 
intensely pruritic. Other common findings include alopecia, 
onychodystrophy, and palmoplantar hyperkeratosis.
In general, Sézary syndrome is more resistant to current 
treatment modalities than mycosis fungoides. The prognosis 
is poor, with a five-year survival rate of 25%. Most patients 
die of opportunistic infections due to immunosuppression.6
Current therapy options
In mycosis fungoides, there are two broad categories of treat-
ment options. These are skin-targeted therapies and systemic 
therapies. In general, skin-directed treatments are first-line 
agents in early-stage disease, and systemic therapy is utilized 
in patients with more extensive or refractory skin disease or 
more advanced disease, often in combination with skin-di-
rected treatments.7 Randomized controlled trials have demon-
strated that in early-stage CTCL, systemic chemotherapy as 
a first-line agent did not lead to improved survival compared 
with skin-targeted therapy.8 Thus, systemic chemotherapy is 
not the treatment of choice in early disease.
Skin-targeted therapy includes topical corticosteroids, 
topical retinoids, topical chemotherapy, radiotherapy, pho-
totherapy, excimer laser, photodynamic therapy, and total 
skin electron beam therapy.4,7 In patients with patch- or 
plaque-stage mycosis fungoides, topical corticosteroids 
and retinoids, topical chemotherapy of nitrogen mustard 
or carmustine, and phototherapy including ultraviolet   Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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A and B therapy tend to be very effective. Because excimer 
laser emits at a 308 nm wavelength within the   ultraviolet 
B range, this also has efficacy in early-stage mycosis 
  fungoides.   Photodynamic therapy has been successfully used 
in treatment-resistant Stage IA–IIB mycosis fungoides, but 
it has less effect in tumor stage or folliculotropic mycosis 
fungoides. Total skin electron beam irradiation is most effec-
tive in early-stage disease but is also useful in patients with 
advanced-stage mycosis fungoides.7
Within systemic therapy are several biologic response 
modifiers, the goal of which is to potentiate the host immune 
system response to neoplastic T cells. This group of medi-
cations includes, but is not limited to, cytokines, retinoids, 
immunotoxins, and vaccination therapy.4 The most com-
monly used biologic response modifier is interferon-α, which 
has rates of complete remission of up to 17%.9 Roughly simi-
lar in response rate is bexarotene, a novel retinoid-  X-selective 
retinoid.10,11 Newer therapies include the use of cytotoxic 
fusion proteins. For example, denileukin diftitox is a fusion 
protein in which diphtheria toxin is linked to interleukin-2. 
In binding to the interleukin-2 receptor on neoplastic T cells, 
this results in inhibition of protein synthesis and cell death.12 
Vaccination with peptides is currently under investigation.7
The treatment regimens for Sézary syndrome are similar 
to those used for mycosis fungoides. However, given that 
Sézary syndrome is not limited to the skin, systemic treatment 
is generally required. Skin-targeted therapies may be used as 
adjuvant treatments. Traditional systemic therapies in Sézary 
syndrome include CHOP (cyclophosphamide, doxorubicin, 
vincristine, and prednisolone), interferon-α with or without 
PUVA (psoralen and long-wave ultraviolet radiation), stem 
cell transplant, and extracorporeal photopheresis.7,13   However, 
the list of systemic therapies has continually increased because 
no one therapy has proven superior in all patients, and the need 
for therapies for recalcitrant disease remains. The National 
Comprehensive Cancer Network has published guidelines on 
the use of many systemic therapies.14
Unmet needs
As described earlier, there are several different types of treat-
ment modalities already in use for mycosis fungoides and 
Sézary syndrome. The choice of treatment is based mainly 
on the patient’s stage of disease. Although those with patch 
and plaque lesions tend to do well, and mycosis fungoides 
itself has a chronic, slowly progressive course, those patients 
in the tumor stage or with lymph node involvement have 
  significantly less durability of response and a higher chance 
of mortality secondary to their disease. Sézary syndrome 
has an even poorer prognosis, with only about a quarter of 
patients living beyond five years from diagnosis.15 Given 
this current situation, novel treatment modalities that will 
render less morbidity and mortality and longer duration 
of response are needed. Thus, the ongoing work with 
romidepsin, a histone deacetylase inhibitor, is an additional 
therapeutic approach for advanced mycosis fungoides and 
Sézary syndrome.
Clinical evidence for romidepsin
In 1993, romidepsin, a novel antitumor bicyclic depsipeptide 
(C24H36N4O6S2), was isolated from the broth culture of a 
Gram-negative, rod-shaped motile bacterium with a single 
polar flagellum, Chromobacterium violaceum No. 968. 
In vitro studies showed that it had weak antibiotic properties 
and that it was able to revert the transformed morphology 
of an H-ras transformed cell to normal.16–18 Additional in 
vitro studies showed that depsipeptide (romidepsin) has 
potent antitumor activities against different human cell lines 
of lung adenocarcinoma, lung squamous cell carcinoma, 
gastric adenocarcinoma, mammary adenocarcinoma, and 
colon adenocarcinoma cell lines.18 Subsequent in vivo inves-
tigations showed that romidepsin significantly inhibited the 
growth of human lung and mammary adenocarcinoma that 
had been implanted and grown under the kidney capsule of 
immunosuppressed BDF1 mice.18 Also, depsipeptide, admin-
istered intravenously or intraperitoneally, prolonged the life 
of mice with different murine and human ascitic and solid 
tumors, including, but not limited to, leukemias, melanoma, 
colon carcinoma, and lung carcinoma.19
Further characterization of romidepsin revealed that it 
works on DNA within the cell nucleus as a histone deacety-
lase inhibitor. By altering the structure of DNA, it causes 
activation and/or repression of key genes in the cell cycle 
and apoptotic cycle (Figure 1). The nucleosome is the basic 
structural unit of chromatin. It is made up of 146 base pair 
DNA wrapped twice around an octamer of core histones, 
which consists of an H3-H4 tetramer and two H2A-H2B 
dimers. The structural components of a histone can be 
broken down into a basic N-terminal tail region, a histone 
fold, and a carboxyterminal region. All of these regions, 
especially the N-terminus protruding from the DNA helix, 
are sites for a variety of covalent modifications, including 
acetylation.20 The hypoacetylation of histones results in a 
condensed chromatic structure, which leads to repression 
of gene transcription, whereas acetylated histones result in 
a more open chromatic structure, which leads to activation 
of gene transcription.17,21,22Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Histone deacetylase inhibitors have several mechanisms 
of action that lead to apoptosis or inhibition of tumor cell 
growth. Increased histone acetylation leads to the activa-
tion of transcription of a few genes that cause the inhibition 
of tumor growth.17 For example, p21WAF1 and p27KIP1 (cell 
cycle kinase inhibitors) are some of the most common 
genes induced by histone deacetylase inhibitors.16,23 Histone 
acetylation can lead to a conformational change that recruits 
repressor proteins rather than a transcriptional activator.17 
A number of genes, including cyclin D1, are repressed. 
Activation and repression of gene expression is likely due to 
both direct and indirect effects. For example, the activation 
of a transcriptional repressor would lead to gene repression.17 
Additionally, nonhistone proteins (such as p53, Rb, or Hsp90) 
become acetylated.16
Through a combination of the above mechanisms, the 
end result is that histone deacetylase inhibitors induce the 
accumulation of cells with a 4n DNA content, leading to 
apoptosis; cause upregulation of proapoptotic Fas and FasL 
gene transcription; alter the cell cycle, resulting in loss of 
tumor cells in G1 and S phase;16,23 activate differentiation 
programs; block angiogenesis; stimulate the immune system 
in vivo;23 and cause mitotic arrest through the formation of 
aberrant mitotic spindles, most likely by interfering with 
chromosome attachment.16
Clinical trials have demonstrated that histone deacetylase 
inhibitors have selective toxicity against tumor cells and syn-
ergistic activity with existing therapeutic agents, including 
retinoic acids in acute promyelocytic leukemia, vitamin D 
analogs in prostate cancer cells, and peroxisome proliferator-
activated receptor ligands in lung   adenocarcinoma.23 Also, 
all histone deacetylase inhibitors synergize with ionizing 
radiation (γ-irradiation) to kill tumor cells in vitro and 
in vivo.16,21
There are several classes of histone deacetylases (see 
Table 1). The zinc-dependent histone deacetylases include 
Class I enzymes (histone deacetylases 1, 2, 3, and 8), which 
are located in the nucleus and essential to cell proliferation 
and survival; Class IIa/b enzymes (histone deacetylases 
4, 5, 6, 7, 9, and 10), which move between the cytoplasm 
Ac Ac
Relaxed euchromatin
HDAC
HDACi
Transcription of genes involved in apoptosis
and inhibition of tumor growth
Possible outcomes:
•  �p21WAF1, �P27KIP1, �Cyclin D1 � Cell cycle arrest
•  �Caspase 3, �Caspase 8, �BAX, �BAK � Pro-apoptosis
•  Hsp 90 acetylation (loss of Hsp function)
•  P53, HIF-1α, pRb, STAT-3, Rel-A acetylation � 
               Cell cycle arrest and activation of apoptosis
•  Disruption of the kinetochore
•  Increased reactive oxygen species (ROS) production
Condensed heterochromatin
Transcription blocked
Ac Ac
Figure 1 HDAC mechanism of action.
Abbreviations: HDAC, histone deacetylase; HDACi, histone deacetylase inhibitors.
Table 1 Characteristics and classifications of different histone deacetylase enzymes
HDAC family Class HDAC 
enzyme
Location Substrate Targeted by 
HDACi?
Zinc-dependent i 1,2,3,8 Nucleus Histone Yes
iia/b 4,5,6,7,9,10 Nucleus, 
cytoplasm
Histone and 
nonhistone
Yes
iv 11 Nucleus Unknown Yes
Zinc-independent iii SiRT 
1,2,3,4,5,6,7
Mitochondrial, 
unknown
Nonhistone No
Abbreviations: HDAC, histone deacetylase; HDACi, histone deacetylase inhibitors.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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and the nucleus and have histone and nonhistone substrates; 
and a Class IV enzyme (histone deacetylase 11). The zinc-
independent NAD-dependent histone deacetylases consist of 
Class III SIRT enzymes that have nonhistone substrates and 
are not currently targeted by available histone deacetylase 
inhibitors.16,21,22
Romidepsin is a relatively unusual histone deacetylase 
inhibitor because it is a prodrug that becomes reduced via 
glutathione to an active compound upon entering cells. It 
is then able to interact with zinc at the active site of the 
histone deacetylase Class I enzymes22 and also, in a much 
weaker fashion, the histone deacetylase Class II enzymes.16 
Increased intracellular glutathione is associated with multi-
drug resistance-associated protein-mediated drug transport 
out of tumor cells. Thus, romidepsin may be a more effec-
tive therapy in tumor cells with glutathione-mediated drug 
resistance.16 However, romidepsin is a substrate for the drug 
efflux protein P-glycoprotein. Thus, protein P-glycoprotein 
upregulation could potentially be a major mechanism for 
acquired resistance.16,23
Currently, responses with single-agent histone deacety-
lase inhibitors have been predominantly observed in advanced 
hematologic malignancies, including non-Hodgkin’s T cell 
lymphoma, Hodgkin’s lymphoma, and myeloid malignancies, 
with few responses in solid tumors.22
In 2002, Sandor et al conducted a Phase I trial in patients 
with advanced or refractory neoplasms.24 Their goals were to 
define the maximum tolerated dose of romidepsin, charac-
terize the toxicities and pharmacokinetics when the medica-
tion was given on days 1 and 5 on a 21-day dosing schedule, 
and seek evidence of antineoplastic activity. Thirty-seven 
patients with advanced or refractory neoplasms were given 
romidepsin via a four-hour infusion on days 1 and 5 of a 
21-day cycle. Because of preclinical data in dogs suggesting 
cardiac toxicity, patients were monitored with continuous 
cardiac monitoring, serial cardiac enzymes, electrocardi-
ography (ECG), and nuclear ventriculography. Romidepsin 
doses were started at 1 mg/m2 and escalated through a 
total of eight dose levels to a maximum of 24.9 mg/m2. 
Toxicities were then graded according to the National 
Cancer Institute Common Toxicity Criteria. A dose-limiting 
toxicity was defined as any Grade 4 hematologic toxicity 
and any Grade 3 or 4 nonhematologic toxicity, excluding 
alopecia. The maximum tolerated dose was defined as the 
dose below which at least two of six patients experienced 
dose-limiting toxicity. Lastly, the pharmacokinetics was 
determined using a liquid chromatography/tandem mass 
spectrometry method.
In preclinical studies, greater antitumor activity was 
seen with an intermittent dosing schedule rather than daily 
because of greater host tolerance and ability to give higher 
individual doses.24 Also, short infusions (0.5–4.0 minutes) 
and prolonged infusions (.24 hours) caused the greatest 
toxicity.24 Thus, infusions of four hours were used in this 
study to allow for the highest individual doses and least 
toxicity.24 In preclinical studies, QT interval prolongation 
and ST segment abnormalities were observed in Beagle 
dogs treated with rapid infusions of romidepsin. At lethal 
doses, hemorrhages were detected in multiple organs, 
including the heart.25
The end results of this trial were based on 37 patients 
treated with a total of 88 cycles, ranging from one to eight 
cycles per patient. This trial concluded that the maximum 
tolerated dose of romidepsin was 17.8 mg/m2. At this dose, 
one patient had a dose-limiting toxicity of hypocalcemia. 
At a dose of 24.9 mg/m2, the major dose-limiting toxicities 
were fatigue (three patients), transient thrombocytopenia, 
hypophosphatemia, and anorexia (two patients each), and 
nausea, vomiting, and hypocalcemia (one patient each). The 
side effect of fatigue was not associated with anemia or other 
defined biochemical abnormalities. This tended to be mild at 
the maximum tolerated dose but severe at dosing greater than 
the maximum tolerated dose. The hematologic changes were 
rapid and transient, suggesting a mechanism other than toxic-
ity to early myeloid precursors. In fact, the thrombocytopenia 
and neutropenia were maximal at days 5 and 10, similar to 
the lifespan of these cells in circulating blood, suggesting 
that romidepsin may affect mature cells. The patients had 
no complications due to these toxicities. Although revers-
ible ST/T wave flattening and mild reversible dysrhythmias 
were seen on post-treatment ECG, no clinically significant 
changes were seen in the left ventricular ejection fraction. 
One patient did develop atrial fibrillation during an episode 
of severe nausea and vomiting, but it was unclear whether 
this was incidental or truly secondary to romidepsin. Serial 
measurements of cardiac output by nuclear ventriculography 
showed no clinically significant decreases in cardiac output 
before and after treatment. Nausea and vomiting were associ-
ated with drug infusion. It is possible that the ECG changes 
were related to the use of antiemetics, which were ondanse-
tron, prochlorperazine, and metaclopromide.26 There was no 
evidence for cutaneous necrosis at the intravenous catheter 
site and there were no patients with alopecia or mucositis. 
One patient did obtain a partial response after   treatment, 
and biologic assays confirmed the ability of the serum from 
patients treated with romidepsin to induce cell cycle arrest Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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in vivo, as well as confirmed an increase in   histone   acetylation 
in circulating mononuclear cells.
In a Phase I trial conducted at the National Cancer   Institute, 
romidepsin was tested as single-agent treatment in four patients 
with T cell lymphoma (see Table 2).27 The study objective was to 
demonstrate that the inhibition of histone deacetylase is a novel 
and potentially effective therapy in this population of patients. 
In this investigation, the patients underwent a four-hour infu-
sion of 12.7 or 17.8 mg/m2 on days 1 and 5 of a 21-day cycle. 
The   disease responses were scored by World Health Organiza-
tion criteria and toxicities were scored by the National Cancer 
  Institute Common Toxicity Criteria. The patients’ treated 
peripheral mononuclear cells and fine needle aspirates from 
tumors were then used to perform histone acetylation assays.
The first and second patients were both males aged 53 and 
63 years and diagnosed with Sézary syndrome. Neither had 
responded to previous chemotherapy (cyclophosphamide, 
doxorubicin, vincristine, and prednisone, or cyclophosph-
amide, vincristine, and prednisone). After treatment with 
romidepsin, both had a rapid decrease of circulating Sézary 
cells, as well as improvement of skin erythema and edema. 
There was an increase in histone acetylation of peripheral 
mononuclear cells. Patient 1 was removed from the study 
after four cycles because he developed multiple subcutane-
ous abscesses of methicillin-resistant Staphylococcus aureus. 
Patient 2 was removed from the study after five cycles due to 
pruritus and erythema that persisted despite therapy.
The third patient was a 78-year-old male with tumor-
stage CTCL. He had not responded to topical therapies 
or total skin electron beam therapy. After the first cycle of 
romidepsin was completed, a fine needle aspiration of two 
lesions was performed. It showed many cells with vacuoliza-
tion and nuclear fragmentation, suggesting that a significant 
population of tumor cells was affected by treatment. After 
six cycles, there was clearing of almost all of the tumors. 
Five lesions that initially responded to treatment eventually 
progressed and were treated with radiation.
The fourth patient was a 53-year-old male with unspeci-
fied peripheral T cell lymphoma. Prior to enrolling in the 
study, he had progression of his disease after one cycle 
of etoposide, prednisone, vincristine, cyclophosphamide, 
and doxorubicin. After initiation of romidepsin, there was 
clearing of his skin nodules and plaques, as well as lymph-
adenopathy on computed tomography scan. After the eighth 
cycle, he had complete remission.
In conclusion, three patients with CTCL had a partial 
treatment response, and one with unspecified peripheral T 
cell lymphoma had a complete response. Sézary cells iso-
lated from patients after treatment had an increase in histone 
acetylation. Thus, romidepsin showed some effectiveness 
as single-agent treatment in patients with refractory T cell 
lymphomas.
On the basis of the observed responses in the Phase I 
National Cancer Institute trial, a Phase II trial of romidepsin 
in patients with CTCL was performed to evaluate the efficacy 
of the medication.28 This trial was limited to patients with 
relapsed, refractory, or advanced (Stage IIb–IVb) CTCL, 
subtypes mycosis fungoides or Sézary syndrome, who had 
received no more than two prior cytotoxic regimens. There 
were no limits on other types of therapy. This protocol 
was later expanded to include patients who had had prior 
  cytotoxic regimens.
Romidepsin was initially given as a four-hour infusion 
of 18 mg/m2 on days 1 and 5 of a 21-day cycle. This was 
later decreased to a more tolerable schedule of 14 mg/m2 
on days 1, 8, and 15 of a 28-day cycle. The doses were 
Table 2 Summary of patient characteristics and outcomes from a Phase i trial of four patients
Patient 
number
Age Diagnosis Previous treatment Adverse effects Outcome
1 53 Sézary 
syndrome
Cyclophosphamide, 
doxorubicin, 
vincristine, prednisone
Multiple subcutaneous 
MRSA abscesses
PR
2 63 Sézary 
syndrome
Cyclophosphamide, 
vincristine, prednisone
Pruritus, persistent 
erythema
PR
3 78 Tumor 
stage CTCL
Topical therapies, 
total-skin electron 
beam therapy
PR
4 53 Peripheral 
T cell 
lymphoma, 
NOS
Etoposide, prednisone, 
vincristine, 
cyclophosphamide, 
doxorubicin
CR
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; PR, partial response; CTCL, cutaneous T cell lymphoma; NOS, not otherwise specified; CR, complete 
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either held or reduced to 10.5 mg/m2 depending on absolute 
neutrophil count, platelet count, or Grade 3 or worse non-
hematologic toxicity. The doses were increased to 17.5 mg/m2 
in the absence of toxicity. Radiotherapy of nonresponding 
lesions was allowed for patients with evidence of over-
all response. These irradiated lesions were not included 
in the final response assessment to romidepsin. Patients 
were given electrolyte supplementation to achieve serum 
magnesium .0.85 mmol/L and potassium .4 mmol/L 
before drug administration, given that T wave and ST seg-
ment abnormalities and QT interval prolongation were 
earlier findings associated with histone deacetylase inhibitor 
therapy. Medications that prolong the corrected QT interval 
(QTc) or interfere with cytochrome (CYP)3A4 metabolism 
were excluded because some studies showed that romidepsin 
may be metabolized by CYP3A4. The response evaluation 
included assessment of skin or visceral involvement, lymph 
node disease, bone marrow involvement, and flow cytometry 
of blood. Complete response was defined as clearing of all 
known sites of disease. Partial response was defined as a 
response in the skin or lymph nodes. Blood samples were 
collected before and after several time points of medication 
infusion for pharmacokinetic analysis.
Among the 71 patients enrolled, there was a median of 
four prior treatments. Sixty-two patients (87%) had advanced-
stage disease (Stage IIb = 15, Stage III = 6, Stage IV = 41). 
Complete responses were seen in four patients (6%), and 
a partial response was seen in 20 patients (28%), for an 
overall response rate of 34% (Table 3). Of the patients with 
a complete response, one patient had mycosis fungoides 
and three had Sézary syndrome. Two patients remain in 
complete remission at 26 and 63 months. Of the 20 patients 
with a partial response, three are still in partial remission 
after 11, 13, and 82 months. Of the remaining 17 patients 
with a partial response, 10 developed disease progression; 
three withdrew; three came off the study after experiencing 
an adverse event of fatigue, infection, or hypotension; and 
one patient died. Twenty-six patients had stability of disease. 
Among patients with either complete or partial response, 
median time to response was two months, and the median 
duration of overall response was 13.7 months. The median 
time to disease progression was 15.1 months for patients 
with either a complete or partial response, 5.9 months for 
patients with stable disease, and 1.9 months for patients who 
had disease progression as the best response or who were 
nonevaluable. The overall responses and response durations 
were similar to those seen after chemotherapy, bexarotene, 
or denileukin diftitox.
Toxicities included nausea and vomiting, fatigue, and 
transient thrombocytopenia and granulocytopenia. In addi-
tion to those mentioned above, which were all previously seen 
toxicities, 38 patients (54%) developed infections, includ-
ing bacterial infections of the skin and upper respiratory, 
pulmonary, gastrointestinal, and urinary tracts, along with 
bacteremia and sepsis. These complications were not found 
to be related to neutropenia. Based on serial troponin I val-
ues, multiple-gated acquisition scans, or echocardiograms, 
there was no evidence of acute or cumulative cardiac dam-
age. There was an increase in the QTc of 14 msec, for which 
clinical significance is still unknown.
Three total deaths occurred during the study and three 
within 30 days of study removal. Of the three deaths that 
occurred during the study, two patients died from sepsis due 
to Escherichia coli and methicillin-resistant Staphylococcus 
aureus on days 10 and 12 after romidepsin was administered, 
respectively. One patient who had a partial response died after 
his treatment course was complicated by atrial fibrillation. He 
had a past medical history of hypertension and severe valvular 
heart disease. His atrial fibrillation was treated with warfarin 
and digoxin. On autopsy, he was shown to have hypertrophic 
cardiac disease with significant valvular pathology. It was felt 
that his death could not be clearly attributed to romidepsin 
and that he had other factors that could have predisposed 
him to sudden death.
The authors’ conclusion was that romidepsin has single-
agent clinical activity, with significant and durable responses 
in patients with refractory CTCL. Also, because patients with 
Sézary syndrome are generally more refractory to available 
therapies, it was encouraging that three patients with Sézary 
syndrome had a complete response to romidepsin, with one 
patient continuing in complete remission at 63 months, more 
than 55 months after romidepsin was discontinued.
An open-label, prospective, single-arm multicenter 
trial in eight countries that supported the US Food and 
Drug Administration application for romidepsin in CTCL 
Table 3 Summary of responses from a Phase ii trial
Type of response Total n = 71 Response duration 
(months) Number %
CR 4 6 6–63*
PR 20 28 1–76*
SD 26 37 3–11
PD 15 21 –
NE 6 8 –
Note: *At least one patient with sustained response at time of report.
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; 
PD, progressive disease; NE, not evaluable.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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has shown similar efficacy in skin response.29 In this trial, 
96 patients with Stage IB–IVA CTCL who had failed at least 
one prior systemic therapy were recruited. Patients received 
romidepsin 14 mg/m2 by intravenous infusion on days 1, 8, 
and 15, every 28 days.
Response to the medication was assessed by determining 
the total tumor burden, which included cutaneous disease 
and lymph node and blood involvement. Cutaneous tumor 
burden was measured using the severity-weighted assess-
ment tool (SWAT) and erythroderma scores. Response 
Evaluation Criteria in Solid Tumors (RECIST) methodol-
ogy was used to assess abnormal lymph nodes, and the 
presence of Sézary cells was assessed by flow cytometry. 
A complete response was defined as complete resolution 
of disease in all three body compartments, and a partial 
response was defined as $50% improvement in the sum 
of the three assessments with $30% improvement in the 
skin, no worsening lymph nodes or Sézary cells, and no 
new tumors.
The study results showed an objective response rate of 
34% and a complete response rate of 6% (Table 4). Response 
was seen in all stages of the disease and in all compartments 
as well. In the 37 patients with involvement of the blood, 
12 patients (32%) had a response to romidepsin treatment, 
including two patients with a complete response. The median 
time to response was two months and the median   duration of 
response was 15 months. This is similar to the first Phase II 
trial and lends additional support for romidepsin as a thera-
peutic option for treatment-refractory CTCL. Also, 43% 
of 65 patients had a clinically meaningful improvement in 
pruritus (measured using a 100 mm visual analog scale), 
which lasted for a median duration of six months. This 
occurred despite exclusion of topical or systemic steroids 
and antihistamines in this study.
Similar side effects of gastrointestinal disturbances, 
fatigue, and weakness were noted (Table 5). In terms of car-
diac side effects, reversible nonspecific ECG changes were 
noted in some patients. Because previous studies suggested 
that romidepsin may prolong the QTc, this trial excluded 
people with known significant cardiac abnormalities and 
those receiving QTc-prolonging drugs. In addition, for the 
first time, assessments were made of the QTcF change from 
baseline before and after antiemetics were administered. 
This demonstrated that, in this group of patients, the mean 
contribution of antiemetics to the QTcF was 1.3 msec and 
that of romidepsin was 4.6 msec. No patient had functional 
cardiovascular changes of symptoms associated with pro-
longation of the QTc.
Although the first clinical trial conducted by the 
National Cancer Institute revealed cases of neutropenia, 
leukopenia, and thrombocytopenia, only thrombocytopenia 
was observed in more than 10% of patients in the second 
study. Tumor lysis syndrome was also observed. In this 
trial, there was QTc   prolongation, but none was felt to be 
clinically   important.   However, patients with known QTc 
prolongation were excluded, and magnesium and potassium 
levels were normalized before starting therapy. Romidepsin 
appears safe, with the most common adverse events related 
to treatment being gastrointestinal issues, ie, nausea, vomit-
ing, and diarrhea.
In order to demonstrate that romidepsin is effective 
at inducing gene expression, different biomarkers in the 
blood and tumor biopsy samples of CTCL patients have 
been studied. In a study by Bates et al, four such   biomarkers 
were investigated.25 These were histone H3 acetylation, 
Table  4  Summary  of  responses  from  a  Phase  ii  trial  with 
Stage iB–ivA disease
Type of 
response
Patients Total n = 96
Early-stage 
disease (n = 28)
Advanced-stage 
disease (n = 68)
Number      %
CR 1 5 6 6
PR 6 21 27 28
SD NR NR 45 47
PD NR NR 10 10
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; 
NR, not reported; PD, progressive disease.
Table 5 Comparison of most common drug-related toxicities 
reported in two Phase ii trials
Toxicity Percentage of patients 
Piekarz et al28 
(n = 71)
Whittaker et al29,* 
(n = 96)
Nausea 52 56
Fatigue/asthenia 41 44
vomiting 19 26
Anorexia 21 20
Diarrhea 8 14
Headache 7 14
Dysgeusia 19 24**
Thrombocytopenia 40 11
Anemia 37 10
Leukopenia 29 –
Granulocytopenia 36 –
Hypoalbuminemia 20 1
Hyperglycemia 18 1
Hypocalcemia 42 –
Hypomagnesemia 15 –
Notes: *Nonserious side effects affecting less than 10% of patients not reported in 
this study; **13 of these patients experienced ageusia.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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ABCB1 gene expression (a reliable marker of p21   induction 
in peripheral blood mononuclear cells) in tumor biopsy 
samples, and blood fetal hemoglobin levels, which are a 
potential surrogate marker for drug effect on normal bone 
marrow.
In terms of global histone acetylation, there was an overall 
increase. At four hours, 73% of patients had evidence of at 
least a two-fold increase in global histone acetylation in cir-
culating peripheral blood mononuclear cells, which persisted 
at that level or higher at 24 hours in 43% of patients. The 
global increase in histone acetylation at 24 hours not only 
was somewhat correlated with pharmacokinetic parameters 
but there was a trend that correlated with patient response 
(P = 0.06).
In blood and tissue samples, 56% of patients had 
ABCB1 levels two-fold or higher than baseline at four 
hours, and 37% had levels two-fold or higher than baseline 
at 24 hours. This can be compared with cell line models in 
which ABCB1 was induced to a much greater degree. It may 
be that constraints in the ABCB1 promoter are present in 
normal circulating white blood cells and prevent a greater 
increase. If so, circulating Sézary cells could in fact show a 
higher rate of gene expression changes in response to histone 
deacetylase inhibitors.
In terms of blood fetal hemoglobin levels, 73% of patients 
had a greater than two-fold increase, and 60% had a greater 
than four-fold increase. This occurred over a median time to 
peak of 99 days, which is compatible with a red blood cell 
half-life of 120 days and the fact that blood fetal hemoglobin 
expression may only be modulated in erythroid progenitors 
found in the bone marrow that populate the circulation. 
This suggests that the effect of repeated medication doses is 
cumulative. Future studies are needed to validate the ability 
of these biomarkers to predict the response of CTCL patients 
to romidepsin.
Pharmacogenetics
The future of medicine is headed toward pharmacogenetics, 
in which medications are tailored to work effectively for 
individuals based on their genetic variation. Part of making 
medications pharmacogenetically specific for people involves 
studying the effects of pharmacogenetic covariates on the 
pharmacokinetics of specific drugs in specific diseases. 
One such study looked at the effect of those variables on 
the pharmacokinetics of romidepsin in patients with T cell 
lymphoma.30
In this study, 98 patients in a Phase II trial were evaluated 
in terms of polymorphic variations in CYP3A4, CYP3A5, 
SLC01B3, and ABCB1, all of which encode genes thought 
to be involved in romidepsin disposition. Blood samples 
were obtained before drug administration, at the end of 
infusion, and at several time points during infusion and 
after infusion was complete. Sixty-four patients had cuta-
neous T cell lymphoma and 34 patients had peripheral T 
cell lymphoma.
Previous studies have shown that romidepsin metabo-
lism in vivo is primarily by CYP3A4 and to a lesser extent 
by CYP3A5. Preclinical studies in rats showed that 66% 
of the drug was excreted into bile. This was thought to be 
mediated via P-glycoprotein encoded by ABCB1, for which 
romidepsin has been identified as a substrate. Indeed, as pre-
viously mentioned, this is a potential pathway for resistance 
to romidepsin. Romidepsin is also a substrate of the organic 
anion transporter OATP1B3, which is an influx transporter 
encoded by SLC01B3.
Patient variability was 37%. The overall estimated half-
life was 3.5 hours. Individuals carrying the ABCB1 2677TT, 
2677GA, or 2677AA genotypes trended toward a decreased 
clearance compared with people carrying only reference alleles 
or the ABCB1 2677GT genotype, but this was not statistically 
significant. Genetic variation in CYP3A4/5 and SCL01B3 had 
no effect on the systemic exposure. The authors concluded 
that moderate interindividual variability in romidepsin phar-
macokinetics had no clinically relevant correlates.
Tolerability and safety
As previously mentioned, in preclinical studies, QT interval 
prolongation and ST segment abnormalities were observed 
in Beagle dogs treated with rapid infusions of the medica-
tion, and cardiac hemorrhages were detected on autopsy 
when lethal doses were administered. Because of these 
concerning cardiac findings, there was extensive serial 
cardiac monitoring. In a follow-up to the National Cancer 
Institute Phase II trial,31 the data from cardiac monitor-
ing of 42 patients in that investigation were summarized. 
Cardiac dysfunction in relation to chemotherapy can be 
divided into two types. In Type I chemotherapy-related 
cardiac dysfunction, there is myocardial damage that may 
lead to impaired cardiac function and overt congestive 
heart failure. For example, this is known to occur with the 
use of anthracyclines or high doses of alkylating agents. 
In Type II chemotherapy-related cardiac dysfunction, the 
medication is not associated with myocyte damage, there 
is reversibility of any cardiac changes, and there is a lack 
of dependence on dose or re-exposure to the agent. This 
occurs, for example, with herceptin.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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In this retrospective cardiac summary, 2051 ECGs and 
161 evaluations of left ventricular ejection fraction were 
  studied. Although T wave flattening or ST segment depres-
sion was observed in greater than half of post-treatment 
ECGs, these were not associated with elevated cardiac 
  troponin I or creatine phosphokinase or altered left ven-
tricular function, as evidenced by echocardiograms obtained 
at the time of the patient’s worst ECG abnormalities. No 
significant changes in left ventricular ejection fraction were 
observed. This was found to be true even if patients had been 
treated for prolonged periods of up to 50 months. Also, there 
was no clinically significant increase in serum troponin I 
even in patients who had prior anthracyclines and who at 
baseline had higher levels of cardiac troponin I than patients 
who had not been previously treated with anthracyclines.
Post-treatment ECGs had an average QTc prolongation 
of 14.4 msec. However, all patients received ondansetron, a 
serotonin inhibitor, for antiemetic therapy, which has been 
associated independently with QTc prolongation by a mean 
of 15 msec. This effect is seen with dolasetron,   ondansetron, 
and palonosetron but not with granisetron. However, in 
general, the effects on ST/T waves and QTc have been seen 
for histone deacetylase inhibitors with different chemical 
structures from romidepsin, suggesting that this is a class 
effect due to the overall underlying mechanism of action.31 
Other trials using histone deacetylase inhibitors other than 
romidepsin have shown the same ECG changes that may be 
related to dosing and schedule.32
In general, Class II histone deacetylases repress the activ-
ity of MEF2, a transcription factor that when released allows 
expression of a program of genes that result in cardiac hypertro-
phy. In contrast, Class I histone deacetylases (which romidepsin 
predominantly inhibits) are involved in the repression of an 
antihypertrophy program. The echocardiograms performed in 
the Phase II National Cancer Institute trial showed no evidence 
of significant change in cardiac muscle thickness.
In terms of fatalities in patients treated with romidepsin, 
there have been six deaths in over 450 patients treated, five of 
which occurred 16–60 hours after the medication had been 
given. Four of those five patients had significant risk factors for 
sudden death. For example, one patient had a neuroendocrine 
tumor, left ventricular hypertrophy, and uncontrolled hyperten-
sion. The authors suggested that, in future, it would be prudent 
to exclude patients at risk for sudden death in these trials.
The conclusion of the cardiac summary was that 
romidepsin is not associated with myocardial damage or 
impaired cardiac function. The potential effect of increased 
QTc remains something that is under continued study.
As mentioned earlier, other observed side effects were 
fatigue, nausea and vomiting, thrombocytopenia, and 
neutropenia. Fatigue was not significant at the maximum 
tolerated dose. Nausea and vomiting were associated with 
infusion of the medication. The hematologic effects were 
rapid, transient, and not associated with any complications. 
Due to the timing of these hematologic changes, it is felt 
that this is not an effect on early myeloid precursors but on 
mature cells.
Cost-effectiveness
Although there are several modalities available for the 
treatment of CTCL, the disease process tends to be progres-
sive, and stability is short-lived in patients with advanced 
disease. There is still a need for new therapies and treatment 
regimens that will lead not only to remission but to consis-
tent durable responses. If this can be accomplished, there 
will be a reduction in the financial burden on the health 
care system, families, treatment centers, and palliative care 
centers. To date, there are no studies that have investigated 
the financial impact of romidepsin on CTCL.
Appropriate patient populations
Based on the clinical trials performed, romidepsin is rec-
ommended for use in mycosis fungoides patients with 
Stage IIb–IVb disease who have failed recommended first-
line treatments. Stage IIb disease includes the presence of 
skin tumors. Stage III includes patients with erythroderma 
and Stage IVa/b patients with blood or visceral involvement. 
Romidepsin is also appropriate for use in patients with Sézary 
syndrome, as described earlier.
Dosing
Romidepsin was found to have a maximum tolerated dose 
of 17.8 mg/m2 and has been used in intravenous dosing 
schedules of 10.5, 14, or 17.5 mg/m2 on days 1, 5, and 8 
of a 28-day cycle or 12.7 or 17.8 mg/m2 at days 1 and 5 of 
a 21-day cycle. Doses higher than 17.8 mg/m2 had dose-
limiting toxicities and were not well tolerated. Romidepsin 
was administered as a four-hour intravenous infusions. The 
current dosing schedule approved by the US Food and Drug 
Administration is 14 mg/m2 administered over a four-hour 
period on days 1, 8, and 15 of a 28-day cycle.
Conclusion
CTCL comprises a broad group of neoplasms of skin-
homing T cells. The most common form of CTCL is mycosis Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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fungoides, and the less common form is Sézary syndrome. 
Although these two disease entities appear to be at opposite 
ends of a spectrum of severity, advanced mycosis fungoides 
and Sézary syndrome both need treatments that provide 
not only decreased morbidity and mortality but also a more 
durable period of response.
Romidepsin is a novel medication that utilizes his-
tone acetylation in order to either activate or inhibit 
genes involved in the cell cycle and apoptosis. Its diverse 
mechanisms of action have been demonstrated to be 
tumor-selective and lead to partial and complete remis-
sion. It is generally well tolerated and has response rates 
comparable with those of existing treatments, and no 
clinically significant cardiac side effects can be defini-
tively attributed to the   medication. Whether romidepsin 
independently increases QTc apart from ondansetron and 
the clinical consequences of an increased QTc, eg, torsades 
de pointes, is yet to be seen. Also,   biomarkers will need 
to be further investigated in order to make use of them as 
predictors of disease response and prognosis. So far, studies 
on patients with different alleles coding for the enzymes 
involved in the metabolism of the drug demonstrate that 
there is no significant difference in clearance among a 
diverse population. Romidepsin, in conclusion, is a new, 
minimally immunosuppressive medication that can be 
utilized to treat patients with refractory mycosis fungoides 
or Sézary syndrome.
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